Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

TELA Bio, Inc. TELA

Healthcare  —  Medical Devices
1.26 (0.01) (0.79%) as of 25 Sep
Market cap
$57.3M
P/E
0.0×
Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

TELA Bio, Inc. (TELA) Business Profile

Updated before January 2025

Company Overview

TELA Bio, Inc. (NASDAQ: TELA) is a medical technology company specializing in the development and commercialization of innovative soft-tissue reconstruction solutions. Founded in 2012 and headquartered in Malvern, Pennsylvania, TELA Bio aims to address unmet clinical needs in the field of reconstructive surgery. The company is led by a team of experienced professionals, including Antony Koblish, who serves as the President and Chief Executive Officer. Under his leadership, TELA Bio has grown into a recognized player in the healthcare industry, focusing on improving patient outcomes through advanced surgical solutions.

Core Business Segments

TELA Bio operates primarily in the field of soft-tissue reconstruction, offering a range of products designed to enhance surgical outcomes. The company’s product portfolio is categorized into the following segments:

1. Hernia Repair Solutions

TELA Bio’s OviTex® portfolio is a flagship product line designed for hernia repair and abdominal wall reconstruction. These products combine biologic and synthetic materials to provide strength and durability while promoting natural tissue healing. Key products include:

  • OviTex® Reinforced Tissue Matrix: A unique blend of biologic and synthetic materials that support tissue integration and reduce the risk of complications.
  • OviTex PRS: Specifically designed for plastic and reconstructive surgery, offering a solution for complex hernia repairs.

2. Plastic and Reconstructive Surgery

The company also offers solutions tailored for plastic and reconstructive surgery. These products are designed to address challenges in soft-tissue reconstruction, providing surgeons with advanced tools to achieve optimal outcomes.

  • OviTex PRS: A versatile product that supports soft-tissue repair in reconstructive procedures.

3. Surgical Mesh Solutions

TELA Bio’s surgical mesh solutions are engineered to provide a balance between strength and flexibility, ensuring effective tissue repair while minimizing complications. These products are used in a variety of surgical applications, including hernia repair and abdominal wall reconstruction.

Business Model

TELA Bio operates on a business model that integrates innovative product development with a strong focus on customer support and education. The company generates revenue through the sale of its proprietary products, primarily to hospitals, surgical centers, and healthcare providers. TELA Bio emphasizes:

  • Research and Development (R&D): Continuous investment in R&D to develop cutting-edge solutions that address unmet clinical needs.
  • Surgeon Education: Providing training and resources to surgeons to ensure the effective use of its products.
  • Customer Support: Offering robust customer support to healthcare providers, ensuring seamless product integration into surgical practices.

Strategic Direction

TELA Bio is committed to expanding its product portfolio and market presence. The company’s strategic initiatives include:

  • Product Innovation: Developing new products and enhancing existing ones to address a broader range of surgical needs.
  • Market Expansion: Increasing its footprint in domestic and international markets through strategic partnerships and collaborations.
  • Sustainability Goals: Incorporating sustainable practices in product development and operations to minimize environmental impact.
  • Clinical Evidence: Building a strong body of clinical evidence to support the efficacy and safety of its products, thereby driving adoption among healthcare providers.

Competitive Landscape

TELA Bio operates in a competitive market, facing competition from both established players and emerging companies in the medical technology sector. Key competitors include:

  • Medtronic: A global leader in medical technology, offering a wide range of surgical solutions.
  • BD (Becton, Dickinson and Company): Known for its surgical mesh products and other healthcare solutions.
  • Integra LifeSciences: Specializes in regenerative technologies and surgical solutions.
  • Hernia Mesh Manufacturers: Various smaller companies that produce surgical mesh products for hernia repair.

TELA Bio differentiates itself through its innovative product designs, focus on clinical outcomes, and commitment to surgeon education.

Risk Factors

Like any business, TELA Bio faces several risks that could impact its operations and financial performance. Key risk factors include:

  • Market Dependence: Reliance on the success of its OviTex® product line for revenue generation.
  • Regulatory Challenges: Navigating complex regulatory environments in different markets.
  • Supply Chain Disruptions: Potential disruptions in the supply chain that could affect product availability.
  • Competition: Intense competition from established players and new entrants in the market.
  • Economic Conditions: Economic downturns or changes in healthcare spending that could impact demand for its products.

Recent Developments

TELA Bio has made significant strides in recent years, including:

  • Product Launches: Introduction of new products and enhancements to the OviTex® portfolio.
  • Clinical Studies: Publication of clinical data demonstrating the efficacy and safety of its products.
  • Strategic Partnerships: Collaborations with healthcare providers and organizations to expand market reach.
  • Global Developments: Navigating challenges posed by the COVID-19 pandemic, including supply chain disruptions and changes in surgical practices.

Investment Considerations

Investors considering TELA Bio should weigh the following strengths and risks:

Strengths

  • Innovative Products: A strong portfolio of innovative products that address unmet clinical needs.
  • Market Opportunity: Significant growth potential in the soft-tissue reconstruction market.
  • Experienced Leadership: A seasoned management team with a track record of success.
  • Clinical Evidence: Robust clinical data supporting the efficacy and safety of its products.

Risks

  • Market Dependence: Heavy reliance on a single product line for revenue.
  • Regulatory Risks: Potential challenges in obtaining and maintaining regulatory approvals.
  • Competition: Intense competition from established players and new entrants.
  • Economic Uncertainty: Vulnerability to changes in healthcare spending and economic conditions.

Conclusion

TELA Bio, Inc. is a dynamic player in the medical technology sector, offering innovative solutions for soft-tissue reconstruction. With a strong product portfolio, experienced leadership, and a commitment to improving patient outcomes, the company is well-positioned for growth. However, investors should carefully consider the risks associated with market dependence, regulatory challenges, and competition. Overall, TELA Bio’s focus on innovation and clinical excellence makes it a compelling choice for healthcare providers and investors alike.